Partner, Kleiner Perkins Caufield & Byers (KPCB)
Brook Byers has been a venture capital investor since 1972. He has been closely involved with more than fifty new technology based ventures, over half of which have already become public companies. He formed the first Life Sciences practice group in the venture capital profession in 1984 and led KPCB to become a premier venture capital firm in the medical, healthcare, and biotechnology sectors.
He is currently on the Board of Directors of nine companies, most recently joining CardioDX, Genomic Health Incorporated, Five Prime Therapeutics, OptiMedica, Pacific Biosciences, Inc., Tethys and XDx, Inc. He was formerly a Director of Idec Pharmaceuticals (Chairman), Athena Neurosciences (Chairman), Signal Pharmaceuticals, Arris Pharmaceuticals, Pharmacopeia, Hybritech (Chairman), Genprobe and others. These companies have pioneered the medical use of molecular biology, monoclonal antibodies, molecular diagnostics and genomics.
Brook was President and a Director of the Western Association of Venture Capitalists. He is currently a Board member of the University of California at San Francisco Medical Foundation, the New Schools Foundation, Stanford’s Bio-X Advisory Council, the Stanford Eye Council and TechNet. He was Co-Chair of the five year, $1.4 billion, UCSF Capital Campaign. He received the Distinguished Citizen Award in Life Science from the Commonwealth Club of California in 2006. In 2007, he was awarded the “UCSF Medal” as their honorary degree equivalent. He earned a BS in electrical engineering from Georgia Tech and an MBA from Stanford University.
General Partner, MDV-Mohr Davidow Ventures
Bill Ericson joined MDV in 2000 after more than a decade of working closely with entrepreneurs to start and build innovative businesses in the role of lawyer, board member, entrepreneur and investor. Bill's investment focus at MDV is primarily in life sciences, with a current specific focus on molecular diagnostics and platforms that will enable the vision of personalized medicine. He works closely with a cross-disciplinary team of leading scientists, researchers and entrepreneurs, and seeks to apply technology solutions to life sciences in non-traditional ways. Bill has also led investments in a number of information technology and Internet companies.
In addition to serving on the board of Pacific Biosciences Bill is also on the board of Adamas Pharmaceuticals, Artemis Health, Cellpoint Diagnostics, nLight Photonics, RainDance Technologies, Revenue Science, Sabrix, Tethys Bioscience and Visible Measures.
Prior to MDV Bill founded and ran Venture Law Group's Seattle office. Bill is particularly proud of being a member of the founding team of Rosetta Inpharmatics and serving on its Board of Directors until its acquisition by Merck in 2001.
Bill serves on the Board of Northwestern University School of Law and is a member of the Personalized Medicine Coalition. Bill received his B.S.F.S. from Georgetown University of Foreign Service and J.D. from Northwestern University School of Law.
Institute Director and Professor, Princeton University
David Botstein, Ph.D., is Director of the Lewis-Sigler Institute for Integrative Genomics and Anthony B. Evnin Professor of Genomics at Princeton University, where he has served since 2003. From 1990-2003 he was Chairman of the Department of Genetics at Stanford University. Previously, he was Vice President for Science at Genentech, and today serves on Genentech’s Scientific Resource Board. He is a member of the National Academy of Sciences and the Institute of Medicine, and has received numerous awards for his achievements in science. Dr. Botstein has made fundamental contributions to modern genetics, including the discovery of many yeast and bacterial genes and the establishment of key techniques that are commonly used today. In 1980, Botstein and three colleagues proposed a method for mapping genes that laid the groundwork for the Human Genome Project. Dr. Botstein holds a Ph.D. in Human Genetics from the University of Michigan and an A.B. in Biochemical Sciences from Harvard.
Vice President for Business Affairs and Chief Financial Officer, Stanford University
Randy Livingston is currently Vice President for Business Affairs and Chief Financial Officer of Stanford University. Before joining Stanford in 2001, Mr. Livingston spent 16 years as a finance, marketing, and corporate development executive for several Silicon Valley companies and six years as a consultant at McKinsey & Company. Mr. Livingston currently serves as a director of Genomic Health, eHealth, Inc., and the Stanford Management Company. Mr. Livingston holds a B.S. in Mechanical Engineering from Stanford University and an M.B.A. from the Stanford Graduate School of Business.
Senior Vice President & Chief Financial Officer, Intuitive Surgical
Marshall L. Mohr is Senior Vice President & Chief Financial Officer at Intuitive Surgical, the global leader in minimally invasive robotic-assisted surgery. He joined the Board of PacBio in January 2012. Prior to joining Intuitive Surgical in March 2006, Mr. Mohr was Vice President and Chief Financial Officer of Adaptec, Inc., a leading provider of storage solutions that reliably move, manage and protect critical data and digital content.
Prior to joining Adaptec in July 2003, Mr. Mohr was an audit partner with PricewaterhouseCoopers where he was most recently Managing Partner of the firm's West Region Technology Industry Group and was responsible for the firm’s more than 400-person Silicon Valley accounting and audit advisory practice. He also held a variety of positions at PricewaterhouseCoopers during his 22 years of service and served as the engagement partner on numerous technology companies in the networking and communications sectors.
Mr. Mohr is a CPA and holds a Bachelors of Business Administration degree from Western Michigan University. Mr. Mohr also serves on the corporate boards of Plantronics, Inc. and Atheros Communications, Inc.
President and Chief Operating Officer, Gilead Sciences
Dr. Milligan joined Gilead Sciences in 1990 as a research scientist and was made Director of Project Management and Project Team Leader for the Gilead Hoffmann-La Roche Tamiflu® collaboration in 1996. In 2002, Dr. Milligan was appointed Chief Financial Officer. He was named Chief Operating Officer in 2007 and President in 2008.
Dr. Milligan was named "Bay Area CFO of the Year" in 2006 for companies with revenues greater than $500 million, and he was named the top biotechnology industry CFO in the United States by Institutional Investor magazine in 2006, 2007 and 2008. In 2008, Dr. Milligan joined the board of Biotechnology Industry Organization (BIO), the largest biotechnology industry organization. Dr. Milligan is a Trustee of Ohio Wesleyan University.
Dr. Milligan received his BA from Ohio Wesleyan University, his PhD in biochemistry from the University of Illinois and was an American Cancer Society postdoctoral fellow at the University of California at San Francisco.
Developmental Biology Professor, Stanford University School of Medicine
Dr. Shapiro currently serves as the Virginia and D.K. Ludwig Professor of Cancer Research and the Director of the Beckman Center for Molecular and Genetic Medicine at Stanford University's School of Medicine, where she has been as a faculty member since 1989. Dr. Shapiro is a co-founder and director of Anacor Pharmaceuticals, Inc. In 1989, Dr. Shapiro founded Stanford University's Department of Developmental Biology, and served as its Chairman from 1989 to 1997. Prior to that, Dr. Shapiro served as Chair of the Department of Microbiology and Immunology in the College of Physicians and Surgeons of Columbia University. She received a B.A. from Brooklyn College and a Ph.D. in Molecular Biology from the Albert Einstein College of Medicine.
Dr. Shapiro has received numerous awards and has been elected to the National Academy of Sciences, the American Academy of Microbiology, the American Academy of Arts and Sciences and the Institute of Medicine of the National Academy of Sciences for her work in the fields of molecular biology and microbiology. Dr. Shapiro previously served as a non-executive director of GlaxoSmithKline plc from 2001 to 2006.